## DGX: Quest Diagnostics Incorporated - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.42 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-5.8% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($175.23)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 9 ($1.18M) |
| Sells | 5 ($3.52M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 52.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.8% (+0.1%)
- Blackrock Inc.: 9.0% (-3.0%)
- JPMORGAN CHASE & CO: 7.8% (+99.3%)
- Price (T.Rowe) Assoc: 6.3% (-2.6%)
- State Street Corpora: 4.7% (+0.8%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-5.8% 5d) with bearish MACD, trend may be turning.
2. Insider selling cluster: $3.5M in recent transactions.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.42 suggests fair value with growth premium. Forward P/E 17.6x stretched relative to 6% growth. Insider selling cluster ($3.5M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $19.7B |
| Beta | 0.62 |
| 52W Range | $148.70 - $197.55 |
| Short Interest | 4.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.42 |
| Forward P/E | 17.6 |
| Current P/E | 18.6 |
| YoY Growth | 5.8% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 2.2% to -3.6% (-5.8% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 7.6pp (needs >4.0% for momentum thesis). Underperforming sector by 3.3pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.03x) but short-term weakness (below SMA20). MACD histogram bearish (-0.62), momentum weakening. RSI neutral at 45. OFD pattern: -SUN (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -3.58% (CS: 18) | Weak |
| RSI_14 | 44.7 | Neutral |
| MACD Histogram | -0.62 | Bearish |
| vs SMA20 | 0.983x | Below |
| vs SMA50 | 0.992x | Below |
| vs SMA200 | 1.034x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $182.61
- **Stop Loss:** $175.23 (4.0% risk)
- **Target:** $197.37 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 128
- **Position Value:** $23,374.08
- **Portfolio %:** 23.37%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderately constructive conditions. Fed dovish pivot expectations from weak jobs data and declining VIX suggest improving risk appetite, though narrow breadth at 51% indicates selective participation. Focus on quality sectors benefiting from rate cut expectations.*

### Earnings

**Next:** 2026-01-27 (Est: $2.36)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.50 | $2.60 | +3.9% |
| 2025Q2 | $2.57 | $2.62 | +1.9% |
| 2025Q1 | $2.15 | $2.21 | +2.8% |
| 2024Q4 | $2.18 | $2.23 | +2.1% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*